Regenxbio (RGNX) Misses Q1 EPS by 3c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. ANET
6. DUOL
7. SWKS
8. XYZ
9. CVS
10. FISV

Go back to Regenxbio (RGNX) Misses Q1 EPS by 3c

UPDATE: Regenxbio (RGNX) Reports Additional Positive Interim Phase I/IIa Trial Update for RGX-314 for Treatment of Wet AMD

May 7, 2019 5:07 PM EDT

(Updated - May 7, 2019 5:07 PM EDT)

REGENXBIO Inc. (NASDAQ: RGNX) today an update to its Phase I/IIa trial of RGX-314 for the treatment of wet age-related macular degeneration (wet AMD), since its previously reported interim results. The interim data update announced today includes safety assessments for all subjects enrolled as of April 18, 2019, and new assessments of efficacy at one year after a single administration of RGX-314 for Cohort 3 (6 x 10^10 GC/eye).

As of April 18, 2019, 33 subjects across five dose cohorts have been treated in the Phase I/IIa trial... More